2020–2022[]
|
SVG NEEDED |
Blenrep was approved under the United States Food and Drug Administration's accelerated approval program in 2020. In November 2022, the drug was withdrawn from markets after the DREAMM-3 phase III confirmatory trial, as it had failed to meet the requirements of the FDA's accelerated approval regulations.
| Subsidiaries:
Stiefel Laboratories | Haleon (13%) Predecessors:  |